Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Richard D,Kim

第一单位： Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. richard.kim@moffitt.org.

作者： Richard D,Kim ^[1] ; Nilofer S,Azad ^[2] ; Michael A,Morse ^[3] ; Elizabeth,Poplin ^[4] ; Amit,Mahipal ^[5] ; Benjamin,Tan ^[6] ; Sharon A,Mavroukakis ^[7] ; Massimo,Fantini ^[7] ; Kwong Y,Tsang ^[7] ; Anjum,Zaki ^[7] ; Jose,Torrealba ^[8] ; Philip M,Arlen ^[7] ; Muhammad S,Beg ^[9]

作者单位： Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. richard.kim@moffitt.org. ^[1] Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. ^[2] Department of Oncology, Duke University Medical Center, Durham, North Carolina. ^[3] Department of Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. ^[4] Department of Oncology, Mayo Clinic, Rochester, Minnesota. ^[5] Department of Oncology, Washington University School of Medicine Siteman Cancer Center, St. Louis, Missouri. ^[6] Precision Biologics, Inc., Bethesda, Maryland. ^[7] Department of Pathology, University of Texas Southwestern Medical Center of Dallas, Dallas, Texas. ^[8] Department of Oncology, University of Texas Southwestern Medical Center of Dallas, Dallas, Texas. ^[9]